Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults with primary or secondary relapsed and/or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Detectable levels of cluster of differentiation 33 (CD33) expression.
Failed alternative therapies with established benefit.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2 and adequate organ function.
You may not be if
Acute Promyelocytic Leukemia.
Clinically active central nervous system leukemia.
Active malignant solid tumor.
Pregnant or breastfeeding.
Clareo Health | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
